Author | Kathryn F. Mileham, MD, FACP


Targeted Therapy for Mutation-Driven Metastatic Non–Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors

April 15, 2019

In this article, important concepts in the molecular testing of non–small-cell lung cancer are highlighted.

New Targets and New Mechanisms in Lung Cancer

May 15, 2013

This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.